摘要 Objective: The prevalence of benign prostatic hyperplasia (BPH) rapidly increases after the 4th decade of life. The combination of tamsulosin and dutasteride is a well established therapy for BPH of≥40 g. Non-invasive urodynamic parameters can predict the outcome of medical therapy in patients with BPH. We aimed to correlate these parameters with treatment responses in BPH patients under medical management. Methods: A prospective study was conducted in the Department of Urology in our hospital from May 2014 to April 2015. A total of 100 patients with BPH≥40 g who fulfilled our inclusion criteria were included. Treatment responses were determined by the International Prostate Symptom Score (IPSS) and uroflowmetry. Transabdominal ultrasonography with Doppler was performed to measure prostate volume, intravesical prostatic protrusion (IPP), detrusor wall thickness (DWT), the prostatic capsular artery resistive index (RI) and prostatic urethral angle (PUA) before and 3 months after combination therapy of tamsulosin and dutasteride. Treatment responses were correlated with non-invasive urodynamic parameters. Results: The IPSS, uroflow, age, prostate volume, RI, IPP, DWT and PUA were correlated before and after treatment. Of the 100 patients, 70 (70%) showed significant improvement and 30 (30%) showed no improvement with therapy. Conclusion: Ultrasound bladder parameters are useful tools for measuring the treatment response in BPH patients. Our study shows that RI and DWT significantly correlate with the treatment response in BPH patients. More importantly, pretreatment values of increased IPP and PUA determines the non-improvement of symptoms in BPH patients. Our study suggests the importance of transabdominal ultrasonography (KUB-P) with Doppler for evaluating treatment responses to medical management.
Abstract: Objective: The prevalence of benign prostatic hyperplasia (BPH) rapidly increases after the 4th decade of life. The combination of tamsulosin and dutasteride is a well established therapy for BPH of≥40 g. Non-invasive urodynamic parameters can predict the outcome of medical therapy in patients with BPH. We aimed to correlate these parameters with treatment responses in BPH patients under medical management. Methods: A prospective study was conducted in the Department of Urology in our hospital from May 2014 to April 2015. A total of 100 patients with BPH≥40 g who fulfilled our inclusion criteria were included. Treatment responses were determined by the International Prostate Symptom Score (IPSS) and uroflowmetry. Transabdominal ultrasonography with Doppler was performed to measure prostate volume, intravesical prostatic protrusion (IPP), detrusor wall thickness (DWT), the prostatic capsular artery resistive index (RI) and prostatic urethral angle (PUA) before and 3 months after combination therapy of tamsulosin and dutasteride. Treatment responses were correlated with non-invasive urodynamic parameters. Results: The IPSS, uroflow, age, prostate volume, RI, IPP, DWT and PUA were correlated before and after treatment. Of the 100 patients, 70 (70%) showed significant improvement and 30 (30%) showed no improvement with therapy. Conclusion: Ultrasound bladder parameters are useful tools for measuring the treatment response in BPH patients. Our study shows that RI and DWT significantly correlate with the treatment response in BPH patients. More importantly, pretreatment values of increased IPP and PUA determines the non-improvement of symptoms in BPH patients. Our study suggests the importance of transabdominal ultrasonography (KUB-P) with Doppler for evaluating treatment responses to medical management.
Rajeev Thekumpadam Puthenveetil, Debajit Baishya, Sasanka Barua, Debanga Sarma. Implication of ultrasound bladder parameters on treatment response in patients with benign prostatic hyperplasia under medical management[J]. Asian Journal of Urology, 2015, 2(4): 233-237.
Rajeev Thekumpadam Puthenveetil, Debajit Baishya, Sasanka Barua, Debanga Sarma. Implication of ultrasound bladder parameters on treatment response in patients with benign prostatic hyperplasia under medical management. Asian Journal of Urology, 2015, 2(4): 233-237.
Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
[2]
McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline No. 8. Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research, Public Health Service; 1994. p. 1-17.
[3]
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-9.
[4]
Klingler HC, Madersbacher S, Djavan B, Schatzl G, Marberger M, Schmidbauer CP. Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol 1998;159:191-4.
[5]
Onur R, Ozden M, Orhan I, Kalkan A, Semercioz A. Incidence of bacteraemia after urodynamic study. J Hosp Infect 2004;57: 241-4.
[6]
Ozdemir H, Onur R, Bozgeyik Z, Orhan I, Ogras MS, Ogur E. Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Clin Ultrasound 2005;33:176-80.
[7]
Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol 2000;37:436-42.
[8]
Shinbo H, Kurita Y, Takada S, Imanishi T, Otsuka A, Furuse H, et al. Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia. Urology 2010; 76:1440-5.
[9]
Galosi AB, Mazzaferro D, Lacetera V, Muzzonigro G, Martino P, Tucci G. Modifications of the bladder wall (organ damage) in patients with bladder outlet obstruction: ultrasound parameters. Arch Italurol 2012;84:263-7.
[10]
Cho KS, Kim J, Choi YD, Kim JH, Hong SJ. The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation. Med Hypotheses 2008;70:532-5.
[11]
Cho KS, Kim JH, Kim DJ, Choi YD, Kim JH, Hong SJ. Relationship between prostatic urethral angle and urinary flow rate: its implication in benign prostatic hyperplasia pathogenesis. Urology 2008;71:858-62.
[12]
McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol 1972;107:1008-16.
[13]
Ku JH, Ko DW, Cho JY, Oh SJ. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms. Urology 2010;75: 1467-71.
[14]
Kuo HC. Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements and uroflowmetry. Urology 1999;54:90-6.
[15]
Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology 2007;70: 1096-9.
[16]
Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int 2003;91:371-4.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
